

# FendX Completes Pilot Manufacturing Phase and Prepares to Advance to Real-World Assessment of REPELWRAP(TM) Film

## Will evaluate the real-world repelling effectiveness of REPELWRAP(TM) film on surfaces at various test venues

Oakville, Ontario--(Newsfile Corp. - September 4, 2024) - FendX Technologies Inc. (CSE: FNDX) (OTCQB: FDXTF) (FSE: E8D) (the "Company" or "FendX") a nanotechnology company developing surface protection coatings, is pleased to announce that it has successfully completed its pilot manufacturing phase with Dunmore International Inc. and is now moving forward to evaluate the effectiveness of REPELWRAP™ film in real-world settings.

Dr. Carolyn Myers, CEO of FendX states, "With the completion of our pilot manufacturing phase of development, we are excited to embark on real-world testing at various announced test sites. This next phase is crucial, as it will provide valuable insights into the film's performance in real-world settings, guiding us towards finalizing the film for ultimate commercial production." Dr. Myers continues, "FendX acknowledges the invaluable collaboration and expertise that Dunmore International Corp. and McMaster University have provided in finalizing the pilot manufacturing phase. Their support has been pivotal in achieving this milestone and we look forward to building off this success."

### **About Dunmore International Corp.**

Dunmore International Corp. ("**Dunmore**"), a Steel Partners Holdings L.P. (NYSE: SPLP) operating company, is a global manufacturer of engineered coated and laminated films and foils with manufacturing facilities in the U.S. and Germany. Dunmore offers film conversion services such as coating, metallizing, and laminating along with contract film manufacturing and custom film product development. Dunmore services a diverse group of industries including aircraft, spacecraft, photovoltaic, graphic arts & labels, packaging, and insulation. Dunmore is a subsidiary of Steel Partners and is ISO 9001:2015 and OSHA VPP Star certified.

### **About FendX Technologies Inc.**

FendX is a Canada-based nanotechnology company focused on developing products to make people's lives safer by reducing the spread of pathogens. The Company is developing both film and spray products to protect surfaces from contamination. The lead product under development, REPELWRAP™ film, is a protective surface coating film that, due to its repelling properties, prevents the adhesion of pathogens and reduces their transmission on surfaces prone to contamination. The spray nanotechnology is a bifunctional spray coating being developed to reduce contamination on surfaces by repelling and killing pathogens. The Company is conducting research and development activities using its nanotechnology in collaboration with industry-leading partners, including McMaster University. The Company has exclusive worldwide licenses to its technology and IP portfolio from McMaster, which encompass both film and spray coating nanotechnology formulations.

### **ON BEHALF OF THE COMPANY**

*"Carolyn Myers"*

Carolyn Myers

Chief Executive Officer and Director

Contacts:

Dr. Carolyn Myers, CEO and Director

1-800-344-9868

[investor@fendxtech.com](mailto:investor@fendxtech.com)

For more information, please visit <https://fendxtech.com/> and the Company's profile on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca).

*Neither the Canadian Securities Exchange nor the Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.*

### **Forward-Looking Statements**

This news release contains certain forward-looking statements within the meaning of Canadian securities legislation, including with respect to: the plans of the Company; statements regarding the Company's plans to embark on real-world testing on surfaces at various test sites and the timing of such testing and expectation of benefits, insights and results from testing; statements regarding finalizing the film for ultimate commercial production scale-up and commercialization; and products under development and any pathogen reduction benefits related thereto. Although the Company believes that such statements are reasonable, it can give no assurance that such expectations will prove to be correct. Forward-looking statements are statements that are not historical facts; they are generally, but not always, identified by the words "expects," "plans," "anticipates," "believes," "intends," "estimates," "projects," "aims," "potential," "goal," "objective," "prospective," and similar expressions, or that events or conditions "will," "would," "may," "can," "could" or "should" occur, or are those statements, which, by their nature, refer to future events. The Company cautions that forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made and involve several risks and uncertainties. Consequently, there can be no assurances that such statements will prove to be accurate and that actual results and future events could differ materially from those anticipated in such statements.

Important factors that could cause future results to differ materially from those anticipated in these forward-looking statements include: product candidates only being in formulation/reformulation stages; limited operating history; research and development activities; dependence on collaborative partners, licensors and others; effect of general economic and political conditions; and other risk factors set forth in the Company's public filings which are available on SEDAR+ at [www.sedarplus.ca](http://www.sedarplus.ca). Accordingly, the reader is urged to refer to the Company's such filings for a more complete discussion of such risk factors and their potential effects. Except to the extent required by applicable securities laws and the policies of the Canadian Securities Exchange, the Company undertakes no obligation to update these forward-looking statements if management's beliefs, estimates or opinions, or other factors should change.



To view the source version of this press release, please visit <https://www.newsfilecorp.com/release/222042>